Deep knowledge on 
 small-molecule drugs and 
 the 100,000 global patents 
 covering them 

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

How are People Using DrugPatentWatch?

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: EDARBI

« Back to Dashboard
Edarbi is a drug marketed by Arbor Pharms Ireland and is included in one NDA. It is available from two suppliers. There are three patents protecting this drug.

This drug has sixty-six patent family members in thirty-one countries.

The generic ingredient in EDARBI is azilsartan kamedoxomil. There are five drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the azilsartan kamedoxomil profile page.

Summary for Tradename: EDARBI

Patents:3
Applicants:1
NDAs:1
Suppliers / Packagers: see list10

Pharmacology for Tradename: EDARBI

Clinical Trials for: EDARBI

A Comparative Single-Dose Pharmacokinetic (PK) and Safety Study of Azilsartan Medoxomil in Children With Hypertension and in Healthy Adults
Status: Terminated Condition: Hypertension

A Study to Evaluate the Effectiveness and Safety of a Fixed Dose Combination of Azilsartan Medoxomil and Chlorthalidone in Patients With High Blood Pressure Who do Not Achieve Target Blood Pressure Following Treatment With Azilsartan Medoxomil Alone
Status: Completed Condition: Essential Hypertension

A Single- and Multiple-Dose Study of the Pharmacokinetics of TAK-491 in Healthy Chinese Subjects
Status: Recruiting Condition: Healthy Volunteer

TAK-491 (Azilsartan Medoxomil) Compared to Valsartan in Chinese Participants With Hypertension
Status: Recruiting Condition: Essential Hypertension

Pleiotropic Effects of Azilsartan Medoxomil Over Insulin Resistance in Obese, Diabetic and Hypertensive Patients
Status: Recruiting Condition: Hypertension; Obesity; Type 2 Diabetes Mellitus

Safety and Efficacy of Azilsartan Medoxomil in Participants With Mild to Moderate Hypertension
Status: Completed Condition: Hypertension

Study to Evaluate the Efficacy and Safety of Combined Administration of TAK-536CCB and Hydrochlorothiazide in Patients With Grade I or II Essential Hypertension.
Status: Completed Condition: Grade I or II Essential Hypertension

Efficacy and Safety of Azilsartan Medoxomil Combined With Chlorthalidone in Participants With Moderate to Severe Hypertension
Status: Completed Condition: Hypertension

Efficacy and Safety of Azilsartan in Participants With Mild to Moderate Uncomplicated Essential Hypertension
Status: Completed Condition: Essential Hypertension

Efficacy and Safety of Azilsartan Medoxomil in Participants With Essential Hypertension
Status: Completed Condition: Hypertension

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Arbor Pharms Ireland
EDARBI
azilsartan kamedoxomil
TABLET;ORAL200796-001Feb 25, 2011RXNo7,572,920<disabled>Y <disabled>
Arbor Pharms Ireland
EDARBI
azilsartan kamedoxomil
TABLET;ORAL200796-002Feb 25, 2011RXYes7,157,584<disabled>Y <disabled>
Arbor Pharms Ireland
EDARBI
azilsartan kamedoxomil
TABLET;ORAL200796-001Feb 25, 2011RXNo<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: EDARBI

These historical archives are available as an add-on to one-year subscriptions

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Arbor Pharms Ireland
EDARBI
azilsartan kamedoxomil
TABLET;ORAL200796-001Feb 25, 20115,583,141<disabled>
Arbor Pharms Ireland
EDARBI
azilsartan kamedoxomil
TABLET;ORAL200796-002Feb 25, 20115,736,555<disabled>
Arbor Pharms Ireland
EDARBI
azilsartan kamedoxomil
TABLET;ORAL200796-002Feb 25, 20115,958,961<disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: EDARBI

Country Document Number Publication Date
Canada2681143Oct 16, 2008
Morocco28478Mar 01, 2007
Russian Federation2006133898Mar 27, 2008
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2016 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn
`abc